Lionnel Geoffrois

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

Arnaud Méjean, Alain Ravaud, Simon Thézenas et al. · New England Journal of Medicine · 2018 · 909 citations

Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

Jean Louis Lefèbvre, Frédéric Rolland, Margot Tesselaar et al. · JNCI Journal of the National Cancer Institute · 2009 · 280 citations · Full text

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

Sylvie Négrier, Gwénaëlle Gravis, David Pérol et al. · The Lancet Oncology · 2011 · 236 citations

Urology, Genitourinary Cancer, Medicine +5

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11